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Apoptosis involves the cessation of cellular processes,
the breakdown of intracellular organelles, and, finally,
the nonphlogistic clearance of apoptotic cells from the
body. Important for these events is a family of proteases,
caspases, which are activated by a proteolytic cleavage
cascade and drive apoptosis by targeting key proteins
within the cell. Here, we demonstrate that serum re-
sponse factor (SRF), a transcription factor essential for
proliferative gene expression, is cleaved by caspases
and that this cleavage occurs in proliferating murine
fibroblasts and can be induced in the human B-cell line
BJAB. We identify the two major sites at which SRF
cleavage occurs as Asp245 and Asp254, the caspases re-
sponsible for the cleavage and generate a mutant of SRF
resistant to cleavage in BJAB cells. Investigation of the
physiological and functional significance of SRF cleav-
age reveals that it correlates with the loss of c-fos ex-
pression, whereby neither SRF cleavage fragment re-
tains transcriptional activity. Moreover, the expression
of a noncleavable SRF in BJAB cells suppresses apopto-
sis induced by Fas cross-linking. These results suggest
that for apoptosis to proceed, the transcriptional events
promoting cell survival and proliferation, in which SRF
is involved, must first be inactivated.
Cell growth, proliferation, and differentiation are regulated
by numerous, diverse, extracellular signals that modulate gene
expression. The proto-oncogene c-fos represents a classic exam-
ple of an immediate early (IE)1 gene, induced in response to
growth factors and other mitogenic stimuli (1–3). Contained
within the promoter of c-fos and of other IE genes is the serum
response element (SRE), which is essential for strict transcrip-
tional control. Serum response factor (SRF) is a ubiquitously
expressed, 67-kDa protein that binds, as a dimer, to the central
element of the SRE, the CArG box (CC(A/T)6GG) (4). SRF
belongs to the MADS box family of transcription factors, named
after four proteins identified with a common structural domain
(MCM1, Agamous, Deficiens, SRF), all of which regulate tran-
scription via the recruitment of auxiliary factors (5, 6). The
conserved core domain of SRF is sufficient for protein dimer-
ization, DNA binding, and recruitment of ternary complex fac-
tors (TCFs). The TCFs form a subset of the ets family of pro-
teins and include Elk-1, Sap1, and Net/Sap2/Erp (7). In
response to activation of the mitogen-activated protein kinase
signaling pathway, TCFs are rapidly phosphorylated, resulting
in a dramatic increase in their transactivation potential (8–10).
In addition to its role at the SRE, SRF has been shown to
regulate transcription in a TCF-independent manner. The ex-
act function of SRF in this mode of gene expression is unclear.
Within SRF, several amino-terminal phosphorylation sites
have been identified (11–14). More specifically, it has been
demonstrated that phosphorylation of SRF at Ser103 correlates
with c-fos expression (15, 16). A carboxyl-terminal transactiva-
tion domain has also been mapped and shown to interact with
components of the basal transcription machinery, in particular
with Rap74, the large subunit of TFIIF (17, 18). TCF-independ-
ent transcriptional activation by SRF is regulated by the Rho
family small GTPases RhoA, Rac1, and Cdc42hs (19). These
small G-proteins regulate several cytoskeletal processes, and
recent data have suggested that the convergence of LIM kinase
and RhoA signaling, via actin treadmilling, results in the tran-
scriptional activation of some SRF-dependent genes (20). The
mechanism by which this occurs has not yet been characterized
in detail, and RhoA appears to function independently of Rac1
and Cdc42hs, implying that additional signaling pathways may
be involved. The CArG box is frequently found in the promoters
of muscle-specific genes. In this context, it has been demon-
strated that SRF is essential for myogenic differentiation. In-
hibition of SRF by microinjection of anti-SRF antibodies or the
expression of antisense SRF RNA repressed muscle marker
gene expression and blocked the differentiation of myoblasts to
myotubes (21, 22). Moreover, homozygous SRF/ mouse em-
bryos fail to develop mesoderm (23).
Apoptosis, or programmed cell death, is the process by which
surplus or potentially harmful cells are removed from an orga-
nism in a nonphlogistic manner. Loss of the tight control gov-
erning this process can result in inflammation, cancer, stroke,
and many neurodegenerative disorders. Caspases, or cysteine-
dependent aspartate-directed proteases, form an integral part
of the apoptosis machinery (24). In response to some extracel-
lular stimuli, such as Fas ligand, TNF, or genotoxic agents,
caspases are activated in a hierarchical cleavage cascade. Once
activated, they target and inactivate numerous intracellular
* This work was supported by the Wellcome Trust and, in part, by the
Dr. Mildred Scheel Stiftung fu¨r Krebsforschung and the Max Planck
Gesellschaft. The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
‡ Present address: Oxford Glycoscience, The Forum, Abingdon, Oxon
OX14 4RY, United Kingdom.
¶ To whom correspondence should be addressed: School of Biomedical
Sciences, University of Nottingham, Queen’s Medical Centre, Notting-
ham NG7 2UH, UK. Tel.: 44-115-970-9362; Fax: 44-115-970-9926;
E-mail: peter.shaw@nottingham.ac.uk.
1 The abbreviations used are: IE, immediate early; SRE, serum re-
sponse element; SRF, serum response factor; TCF, ternary complex
factor; STAT, signal transducers and activators of transcription; PCR,
polymerase chain reaction; PBS, phosphate-buffered saline; PAGE,
polyacrylamide gel electrophoresis; CHAPS, 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonic acid; DAPI, 4,6-diamidino-2-
phenylindole; DM, double mutant; ZVAD, benzyloxycarbonyl-
Val-Ala-Asp.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 276, No. 36, Issue of September 7, pp. 33444–33451, 2001
© 2001 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org33444
 at A
STO
N
 U
N
IV
ERSITY
 on A
pril 9, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
substrates, including structural components of the cytoskele-
ton, DNA repair enzymes, protein kinases, and transcription
factors as stricken cells are disassembled and removed by
phagocytosis (25).
It is also known that caspases have additional roles beyond
apoptosis, in line with their initial identification as relatives of
the interleukin-1-converting enzyme (26, 27). For example,
cleavage of GATA-1, mediated by caspases, has recently been
demonstrated to block erythroid differentiation (28). In addi-
tion, caspases have been shown to cleave the transcription
factors NF-B, resulting in the down-regulation of NF-B-de-
pendent transcription, and STAT1, suggesting a role for
caspases in mediating transcriptional responses (29–31).
Here we show that SRF also serves as a target for caspases
in several cell types. Two adjacent cleavage sites recognized by
caspases 3 and 7 allow SRF to be cleaved into two major
fragments. Expression of the corresponding fragments reveals
that they are unable to activate SRE-dependent transcription.
Moreover, expression of a noncleavable SRF mutant sup-
presses apoptosis. Our results suggest that SRF is a focal point
for cross-talk between signals promoting cell survival and pro-
liferation and those promoting cell death.
MATERIALS AND METHODS
Plasmid Constructs—pCMV-SRF consists of the coding sequences of
SRF inserted into pCMV5 (32). pCMV-Ncore and pCMV-coreC contain
SRF sequences encoding amino acids 1–222 and 133–508, respectively.
pBS-Ncore245 was produced by amplifying sequences encoding SRF
amino acids 1–245 by PCR from pBOH2-SRF (33) and inserting them as
an EcoRI fragment into pBSKS cut with EcoRI. pCMV-Ncore245 was
generated by ligating the same EcoRI fragment into pCMV5. pCMV-
mycSRFC was constructed inserting sequences encoding amino acids
252–508 into pCMV5m, a generic vector for the expression of Myc-
tagged proteins.
pBO-EATA-SRF, pBO-SASA-SRF, and pBO-DM-SRF were produced
by PCR-based site-directed mutagenesis with the following primers:
EATA, 5-GTGAGAGCTGTCGCTTCAAAGCCAGTGG; SASA, 5-GGT-
GTCGGCGTCTGCCAGCAGTGG.
pCMV-EATA-SRF, pCMV-SASA-SRF, pCMV-DM-SRF were con-
structed by transferring SRF coding sequences from the respective
pBO-SRF plasmids as EcoRI–XbaI fragments.
In pCMV-MSRF, SRF codons 134–169 were replaced by codons 9–44
from MCM1 (34, 35). The restriction sites for the replacement were
produced by PCR-based, site directed mutagenesis with the following
primers: 5MCM, 5-AGAAGGATCCCCTACTAATAATGGG; MCM/
BSP, 5-GCCTTTTTCATGATACCGTGC.
The plasmid pCMV-SRF-Chis has been described elsewhere (36);
pcDNA3-wtSRF-Chis was constructed by transferring SRF coding se-
quences from pCMV-SRF-Chis as an EcoRI-XbaI fragment into
pcDNA3; pcDNA3-DM-SRF-Chis was constructed by combining an
EcoRI-XmnI fragment from pBO-DM-SRF with an XmnI-XbaI frag-
ment from pCMV-SRF-Chis in pcDNA3.
The plasmid pFos-Luc3 contains the c-fos promoter from 711 to
42 fused to the firefly luciferase gene in pGL3-basic (Promega);
pF10H-Luc is a derivative of pFOS-Luc3, from which the SRE has
been deleted (37); pM20-Luc consists of a single copy of the M20 SRE
(38) inserted into the deletion point in pF10H-Luc.
All sequences derived by PCR amplification were subsequently ver-
ified by dideoxy sequencing.
Cell Culture and Transfections—NIH3T3 cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal calf
serum. NIH3T3 cells were plated out at a density of 7.7  104/ml and,
after 24 h, transfected with 0.75 g of the various SRF constructs using
LipofectAMINE (Life Technologies, Inc.), according to the manufactur-
er’s protocol. Eighteen hours after transfection, cells were washed and
serum-starved (0.2%) for 24 h. BJAB cells were grown in RPMI supple-
mented as above. Cells were plated out at a density of 3.3 105/ml and,
after 48 h, transfected by electroporation (290 V, 960 microfarads) using
the gene pulser system (Bio-Rad) with 20 g of DNA containing 4 g of
the various SRF constructs. Eighteen hours after transfection, cells
were serum-starved (0%) for 24 h.
The wtSRF stable cell line (clone 9) was generated by electroporation
of BJAB cells with pcDNA3-wtSRF-Chis, followed by G418 selection at
3 mg/ml for several passages. Clones were isolated from individual cells
by dilution cloning in 96-well plates and identified by Western analyses
with an anti-His monoclonal antibody (Qiagen).
Extract Preparation and Western Analysis—NIH3T3 and BJAB cells
were treated, where appropriate, with staurosporine (250 nM) or CH11
(150 ng/ml), respectively. Cells were harvested in PBS and lysed, on ice
for 20 min, in 10 mM Tris-HCl pH 7.8, 25 mM NaF, 20 mM Na4P2O7, 2.5
mM MgCl2, 5 M Na3VO4, 0.5% Triton X-100, 0.05% SDS, 2.5 mM
benzamide, 200 M phenylmethylsulfonyl fluoride, 2.2 g ml1 aproti-
nin, 1 g ml1 leupeptin, 1 g ml1 pepstatin. Cell debris was then
pelleted by centrifugation, and the clear lysate was removed.
Samples were then analyzed by SDS-PAGE and electroblotting onto
polyvinylidene difluoride membrane. Membranes were probed with N-
terminal (1122; M. E. Greenberg) or C-terminal antibodies (1795;
M. E. Greenberg) or G-20 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) against SRF or anti-Fos (K-25; Santa Cruz Biotechnology) and
visualized by standard ECL procedures (Amersham Pharmacia Bio-
tech) on a luminescence imaging system (Fuji). Reprobing of mem-
branes was carried out in accordance with the manufacturer’s protocol.
Luciferase Reporter Assays—BJAB cells were co-transfected with 5
g of reporter plasmid and 5 g of pCH110 (Amersham Pharmacia
Biotech), as described above. Following serum starvation, cells were
harvested in PBS and lysed in 250 mM KCl, 50 mM HEPES, pH 7.5,
0.1% Nonidet P-40, 10% glycerol. Values obtained from the luciferase
assays were normalized to -galactosidase activity in order to correct
for transfection efficiencies.
Electrophoretic Mobility Shift Assays—Cell extract (15 g) was incu-
bated at room temperature for 10 min in 10 mM Tris, pH 7.5, 100 mM
NaCl, 1 mM dithiothreitol, 1 mM EDTA, 4% glycerol, 80 g/ml herring
sperm DNA, 15 g/ml dI-dC with 0.5 l of antiserum as indicated. Prior
to loading onto a 5% polyacrylamide gel, reactions were incubated for a
further 20 min with the SRE oligonucleotide probe (39). The gel was
then visualized using a Fuji phosphor imaging system.
In Vitro Cleavage Assays—BJAB cells, untreated or incubated with
150 ng/ml CH11 for 10 h, were harvested in PBS. Cell pellets were then
lysed in 25 mM HEPES, pH 7.5, 1 mM EDTA, 5 mM dithiothreitol, 0.1%
CHAPS as described above. Radiolabeled SRF protein was incubated
with 30 g of cell extract, in the buffer described previously, at 37 °C for
1 h. Samples were then analyzed by SDS-PAGE and visualized using a
Fuji phosphor imaging system.
Determination of Percentage Apoptosis—Cells were fixed in 1% (w/v)
formaldehyde in PBS until scored. Scoring was carried out by fluores-
cence microscopy following staining of the cells with 0.0001% (w/v)
4,6-diamidino-2-phenylindole (DAPI) (40).
RESULTS
The experiments described here follow on from our initial
observation of SRF fragments in NIH3T3 cells transiently
transfected with an expression vector for the protein. Two
polyclonal antibodies, one raised against the amino-terminal
portion of SRF (1122) and the other against the carboxyl
terminus (1795), each recognized protein fragments of 30–35
kDa, approximately half the size of full-length SRF (Fig. 1, a
and b, lane 1). To gain a first indication of the nature of these
fragments, we compared their size and immunoreactivity with
truncated forms of SRF expressed from suitably engineered
vectors. Thus, the SRF fragment recognized by 1122 was
larger than Ncore (lane 5) but almost identical in size to
Ncore245 (lane 4), suggesting that it corresponds to SRF amino
acids 1–245. Likewise, the SRF fragment recognized by 1795
was somewhat smaller than coreC (Fig. 1, lane 3) but very
similar in size to SRF-C (amino acids 251–508). These obser-
vations suggest that in NIH3T3 cells SRF is cleaved in half
under certain conditions and that the fragments are stable
enough to accumulate in the cells.
Variations in the level of SRF fragments indicated that SRF
cleavage might be a regulated event, influenced perhaps by the
growth state of the cells. We also noticed a cluster of six aspar-
tate residues in the middle of SRF. In this context, caspases, a
group of aspartate-directed proteases activated in cells under-
going apoptosis, are known to target numerous key proteins as
the process unfolds. To assess a potential role for caspases in
the cleavage of SRF, transfected NIH3T3 cells were treated
with staurosporine for various times in the presence or absence
SRF Down-regulation by Caspases 33445
 at A
STO
N
 U
N
IV
ERSITY
 on A
pril 9, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of ZVAD, to drive cells into apoptosis and inhibit caspase ac-
tivity, respectively. As seen in Fig. 1, c and d, staurosporine
caused an increase in the yield of SRF fragments after 6 and
12 h (compare lanes 2 and 4 with lane 1), which was strongly
counteracted by ZVAD treatment (lanes 3 and 5), implicating
caspases in this phenomenon. In this gel, it is also apparent
that each antibody detects two SRF fragments, indicating that
SRF is cleaved at two or more sites by caspases active in
NIH3T3 cells.
In parallel analyses, NIH3T3 cells were found to enter apo-
ptosis with delayed and heterogeneous kinetics in response to
staurosporine (result not shown). However, a more efficient
means of inducing apoptosis by ligation of Fas proved to be
impossible, since flow cytometric analysis revealed low surface
expression of the receptor on NIH3T3 cells and a corresponding
failure of the antibody (Jo-2) to elicit apoptosis (not shown). For
this reason, we chose to analyze caspase cleavage of SRF fur-
ther in a more appropriate cell system.
The human mature B cell line BJAB expresses high levels of
Fas on the cell surface and can be induced to undergo apoptosis
upon receptor cross-linking by the agonistic monoclonal anti-
body CH11 (41). Thus, 4 h after treatment with CH11,50% of
BJAB cells have entered apoptosis, as assayed by DAPI stain-
ing and cell counting (see Fig. 2a), and by 10 h this number has
risen to 90%. To determine if this process induces SRF cleav-
age, lysates were prepared from BJAB cells either untreated or
incubated for various times with CH11. Cleavage of endoge-
nous SRF was assayed by immunoblotting. Four hours after
CH11 cross-linking, SRF fragments of approximately 30 kDa
are detected and persist for the next 6 h (Fig. 2b, lanes 4–6,
arrowheads). The appearance of these bands is blocked by
ZVAD (lane 7), indicating that they are caspase cleavage prod-
ucts. However, very little decrease in the amount of full-length
SRF is apparent. The prominent 38-kDa species seen in un-
treated cells are unrelated to SRF, since they are not detected
by antibodies specific to the carboxyl terminus of SRF (not
shown), nor are they detected in a DNA-binding assay (see
below).
The integrity of endogenous SRF in CH11-treated BJAB cells
was also investigated by electrophoretic mobility shift assay
with a radiolabeled DNA probe corresponding to the human
c-fos SRE (Fig. 2c). The intensity of the SRF dimer complex is
reduced by 4 h and continues to decrease up to 10 h (arrow).
Moreover, two faster migrating bands appear at 2 h and decay
over the same period (lower arrowheads). All three of these
complexes are supershifted by 1122 (lanes 10–12), which rec-
ognizes the amino terminus of SRF, while 1795 supershifts
only the upper two complexes (lanes 13–15). The simplest in-
terpretation of these observations is that the lower complex
corresponds to a homodimer of amino-terminal SRF fragments,
the DNA-binding domain (amino acids 133–222) residing in the
amino-terminal half of SRF, while the intermediate complex is
a heterodimer in which just one SRF molecule is truncated.
The apparent persistence of full-length SRF in BJAB cells
seen in Fig. 2b is inconsistent with the loss of SRF-SRE com-
plexes (Fig. 2c). To resolve this inconsistency, we generated a
stable cell line that overexpresses a His-tagged version of SRF.
When these cells were treated with CH11 and analyzed for SRF
cleavage (Fig. 2d), we observed almost complete cleavage of
SRF-Chis after 10 h (lane 4), in line with the loss of DNA
binding. We also observed a nonspecific band migrating
slightly faster than SRF-Chis in all lanes, which we believe
co-migrates with endogenous SRF and masks its disappear-
ance in Fig. 2b. From these observations, we infer that SRF is
completely processed in apoptotic BJAB cells.
SRF cleavage was also observed in vitro when 35S-labeled
proteins were incubated in apoptotic BJAB cell lysates. As
shown in Fig. 3b, incubation of SRF with lysates from CH11-
treated cells (lane 3), but not from untreated cells (lane 2), led
to the appearance of four SRF fragments of around 35 kDa,
corresponding in size to those detected in NIH3T3 cells.
The data shown in Fig. 1 indicate that SRF cleavage occurs
in the middle of the molecule, carboxyl-terminal to the DNA
binding domain, referred to as coreSRF (42). The amino acid
sequence of this region of SRF (amino acids 222–271) is de-
picted in Fig. 3a. Within this 10% of SRF, there are six aspar-
tate residues, of which several could constitute sites of caspase
cleavage. Within the remainder of SRF, there are only six
additional aspartates. Mutations were therefore introduced
into SRF to remove two possible caspase consensus sites at
FIG. 1. SRF cleavage products in murine fibroblasts. a, NIH3T3 cells were transfected with expression vectors for full-length SRF (lane 1),
SRFC (lane 2), coreC (lane 3), Ncore245 (lane 4), and Ncore (lane 5). Cells were harvested after 48 h, and lysates were separated on a 12.5%
SDS-polyacrylamide gel and analyzed by immunoblotting (IB) with an antibody against the carboxyl terminus of SRF (Santa Cruz Biotechnology).
b, as in a, except that an amino-terminal SRF antibody (1122) was used. The 67-kDa band detected in all lanes is endogenous SRF. c, NIH3T3
cells were transfected with an expression vector for SRF and serum-starved for 24 h (lane 1) prior to treatment with staurosporine alone (lanes 2
and 4) or with ZVAD (lanes 3 and 5). Cells were harvested at the times indicated, and lysates were separated on a 10% SDS-polyacrylamide gel
and analyzed by immunoblotting with an antibody against the amino terminus of SRF. d, as in c except that a carboxyl-terminal SRF (1795)
antibody was used.
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aspartate residues 245 and 254. Both individual mutants
(EATA245 and SASA254) and the double mutant (DM) were
then tested for cleavage by caspases present in CH11-treated
BJAB cell lysates. Each single site mutant caused the loss of
Cells were harvested at the times indicated and analyzed for apoptosis
by DAPI staining. Data show results from two experiments with dupli-
cate points. b, as in a except that cells were lysed and analyzed for
cleavage of endogenous SRF by immunoblotting (IB) with an amino-
terminal SRF antibody (1122). c, extracts prepared from BJAB cells,
treated with CH11 for the times indicated, were incubated with a
radiolabeled DNA fragment corresponding to the c-fos SRE alone (lanes
2-9) or in the presence of antibodies specific for the amino-terminal
(lanes 10–12) or carboxyl-terminal (lanes 13–15) domain of SRF. The
extract from untreated cells was also incubated with the corresponding
preimmune sera (lanes 16 and 17). Complexes were resolved by elec-
trophoresis on a native 5% polyacrylamide gel. The complex labeled
with an arrow corresponds to the SRF homodimer; the arrowheads
indicate complexes containing SRF cleavage fragments. The identity of
the complex indicated with an asterisk is unclear, but it is not recog-
nized by any of the anti-SRF antibodies. d, a BJAB cell clone overex-
pressing His-tagged SRF (lanes 3 and 4) and a control clone (lanes 1 and
2) were untreated () or incubated with CH11 for 10 h (). Cells were
lysed and analyzed by SDS-PAGE and immunoblotting with an amino-
terminal SRF antibody (1122). Full-length SRF-Chis and its cleavage
fragments are indicated with thin and thick arrows, respectively.
FIG. 2. Induction of SRF cleavage by Fas ligation on B cells. a,
human BJAB cells, grown under normal conditions, were treated with
the agonistic anti-Fas antibody CH11 alone or in the presence of ZVAD.
FIG. 3. SRF cleavage by recombinant caspases. a, sequence of
SRF amino acids 222–271 with aspartate residues highlighted with
asterisks. SRF mutants used in this study are also indicated. Below is
shown a diagrammatic representation of SRF cleavage and the result-
ant pattern of fragments resolved by SDS-PAGE. b, recombinant SRF
(lanes 1–3) or the mutants EATA (lanes 4 and 5), SASA (lanes 6 and 7),
and the double mutant DM (lanes 8 and 9), expressed and labeled with
[35S]methionine by cell-free translation, were incubated with buffer B,
extracts of untreated BJAB cells (), or cells treated for 10 h with CH11
(). Subsequently, reactions were resolved on a 12.5% SDS-polyacryl-
amide gel. c, recombinant SRF, expressed and labeled with [35S]methi-
onine by cell-free translation, was incubated alone (lane 1) or with
recombinant caspase 1 (lane 2), caspase 3 (lane 3), caspase 4 (lane 4),
caspase 6 (lane 5), caspase 7 (lane 6), caspase 8 (lane 7), caspase 9 (lane
8), or caspase 10 (lane 9). Subsequently, reactions were resolved on a
12.5% SDS-polyacrylamide gel. WT, wild type.
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two SRF fragments (Fig. 3b, compare lanes 7 and 5 with lane
3), while the double mutant abolished SRF cleavage in this
assay. A similar set of results was obtained when lysates from
etoposide-treated Jurkat cells were used (not shown), whereby
cleavage was inhibited by the inclusion of ZVAD in the assay.
Moreover, single alanine substitutions of Asp245 and Asp254
had exactly the same effect as the EATA and SASA mutations
on SRF cleavage in vitro (result not shown). Taken together,
these results demonstrate that SRF is cleaved at aspartates
245 and 254 by caspases induced in apoptotic BJAB cells and
active to varying degrees in proliferating NIH3T3 cells. Fur-
thermore, we interpret the results to indicate that SRF can be
cleaved at either but not both sites.
To establish which caspase or caspases are responsible for
SRF cleavage, radiolabeled SRF was incubated with each of
eight active recombinant caspases and then analyzed by SDS-
PAGE. This assay reveals that SRF is cleaved most effectively
by caspases 3 and 7 but also, to a lesser extent, by caspases 6,
8, and 9 to yield similar fragments, suggesting that all five
proteases recognize the same sites (Fig. 3c). In contrast,
caspases 1 and 4 cleave SRF weakly to generate a distinct
pattern of SRF fragments, while recombinant caspase 10 does
not cleave SRF at all.
SRF cleavage by caspases was analyzed further by compar-
ing the susceptibility of SRF mutants to a subset of recombi-
nant caspases (Fig. 4). Caspase 1 cleaved each of the three
mutants similarly to wtSRF, indicating that it does not recog-
nize the sites at Asp245 and Asp254 but does recognize other
sites in the protein. Cleavage of SRF by caspases 3 and 7 is
influenced by both mutations. The mutations at Asp245 (EATA)
result in the loss of two caspase 3 cleavage fragments and
appear to enhance the yield of the others. The same mutant
markedly reduces SRF cleavage by caspase 7. In contrast,
mutations at Asp254 (SASA) lead to the reciprocal pattern of
fragments obtained with caspase 3 but have little effect on SRF
cleavage by caspase 7. The double mutant is resistant to cleav-
age in vitro by caspase 7 and is cleaved only weakly by caspase
3. Moreover, the fragment sizes suggest that caspase 3 may
cleave DM-SRF at a site that is not recognized in wtSRF. In
summary, caspase 7 cleaves at Asp245, while caspase 3 cleaves
predominantly at Asp254 but also, suboptimally, at Asp245 and
an additional site (possibly Asp261).
We surmised that the cleavage of SRF by caspases was likely
to alter the expression of IE genes such as c-fos. Accordingly,
we examined the inducible level of Fos protein in BJAB cells at
increasing times after CH11 treatment. Cells were pretreated
with CH11 for various lengths of time and then with phorbol
ester to induce c-fos expression, which was assayed at the
protein level by immunoblotting. Phorbol ester alone induced
robust Fos expression (Fig. 5a, lane 2), but prior treatment
with CH11 for 1 h or longer reduced and finally abolished
inducible Fos expression (lanes 3–7). Thus, Fas cross-linking
rapidly leads to the inhibition of Fos protein expression. To
ascertain if the loss of Fos protein could be due to proteolysis,
radiolabeled Fos protein was incubated in apoptotic BJAB cell
lysates. However, no degradation of Fos was observed under
FIG. 4. Identification of caspase cleavage sites. a, recombinant
SRF, expressed and labeled with [35S]methionine by cell-free transla-
tion, was incubated alone (lane 1) or with caspase 1 (lane 2), caspase 3
(lane 3), caspase 7 (lane 4), or caspase 9 (lane 5), after which the
reactions were resolved on a 12.5% SDS-polyacrylamide gel. b, as in a
except with the mutant EATA-SRF. c, as in a except with the mutant
SASA-SRF. d, as in a except with the mutant DM-SRF.
FIG. 5. Inhibition of c-fos expression in apoptotic cells. a, hu-
man BJAB cells, cultured for 24 h in low serum (lane 1), were treated
directly with phorbol ester (TPA) (lane 2) or after pretreatment with
CH11 for the times shown (lanes 3–7). Cells were lysed, and Fos ex-
pression was monitored by immunoblotting (IB) with an anti-Fos anti-
body. b, human BJAB cells were transfected with the firefly luciferase
reporter Fos-Luc3 or the mutant F10H-Luc3, which lacks the SRE,
and after culture for 24 h in low serum they were treated with CH11,
ZVAD, or both, as indicated (DMSO, dimethyl sulfoxide vehicle). After
6 h, lysates were prepared and assayed as described. Luciferase activity
is expressed as the ratio of relative light units (R.L.U.) and the -ga-
lactosidase activity expressed from a co-transfected plasmid, whereby
the value for untreated cells is set as unity. c, BJAB cells were trans-
fected with the M20Fos-Luc reporter, which contains the M20 sequence
in place of the SRE, and either control vector (pCMV5), MSRF, NMS4,
or SRFC. After a 24-h culture in low serum, lysates were prepared and
assayed for luciferase activity. Luciferase activity is expressed as the
ratio of relative light units and the -galactosidase activity expressed
from a co-transfected plasmid, whereby the value for cells transfected
with pCMV5 is set as unity.
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conditions in which SRF cleavage was apparent (result not
shown). Therefore, the absence of Fos in CH11-treated cells is
probably due to loss of expression. To assess the extent to which
this effect was due to transcriptional inhibition, the effect of
CH11 on the expression of a c-fos reporter was measured. As
shown in Fig. 5b, CH11 inhibited c-fos reporter expression by
60%, and this inhibition could be blocked by ZVAD. In contrast,
a c-fos reporter from which the SRE had been deleted (F10H)
was refractory to CH11 treatment. It should be noted that
expression of the control gene against which transfection effi-
ciency was normalized was also insensitive to CH11 treatment.
These results suggest that IE promoters containing SREs are
down-regulated early in apoptosis, while other promoters re-
main unaffected.
It remained conceivable that the down-regulation of c-fos
expression could be due to something other than SRF cleavage.
Since cleavage by caspases yields two SRF fragments, we chose
to measure their direct influence on c-fos reporter expression.
To this end, a mutant of SRF with altered DNA binding spec-
ificity was adopted. This mutant (MSRF), which was originally
developed by Treisman and colleagues (38, 43), contains part of
the DNA-binding domain of MCM1 and binds to a sequence
(M20) poorly recognized by SRF. A reporter containing the M20
element therefore has a low basal level of activity when trans-
fected alone into BJAB cells (Fig. 5c), which is elevated when
MSRF is expressed in the cells. In contrast, expression of a
carboxyl-terminal truncation of MSRF corresponding to the
amino-terminal caspase fragment of SRF (NMS4) or the car-
boxyl-terminal fragment of SRF (SRFC) inhibits basal reporter
expression slightly. Taken together, these results indicate that
SRE-dependent c-fos expression is down-regulated early in
apoptosis, that down-regulation is blocked by ZVAD, and that
the fragments of SRF generated by caspase cleavage fail to
maintain expression levels supported by full-length SRF.
Given that the mutation of two predicted caspase sites pro-
duced a mutant of SRF resistant to caspase cleavage in vitro,
we wished to see if the mutant was also resistant to cleavage in
BJAB cells undergoing apoptosis. Thus, BJAB cells expressing
various forms of SRF were treated with CH11, and SRF cleav-
age was assessed by immunoblotting. We observed that muta-
tion of the site at Asp254 had little effect on SRF cleavage in
vivo, whereas cleavage was severely impaired by mutation of
the site at Asp245 (Fig. 6). As expected, no cleavage fragments
were generated from the double mutant, in line with the in
vitro cleavage data.
The availability of a caspase-resistant form of SRF allowed
us to assess directly the importance of SRF cleavage for the
progression of apoptosis. To this end, BJAB cells transfected
with a vector for either wtSRF or DM-SRF were cultured for
24 h in full medium and then treated with CH11. Western
blotting confirmed that wtSRF and DM-SRF are expressed at
identical levels (not shown). After 20 h, cells were fixed and
stained, and apoptotic cells were counted. As shown in Fig. 7a,
CH11 induced apoptosis in 60% of the cells transfected with
either control DNA or an expression vector for wtSRF. By
comparison, in cells transfected with the corresponding expres-
sion vector for DM-SRF, the level of apoptosis induced by CH11
was reduced to 40%. The reduction in the number of apoptotic
cells due to the expression of a cleavage-resistant SRF is re-
markable, because we routinely achieve a transfection effi-
ciency of no more than 50%, as gauged by transfection of a
vector for GFP. Moreover, the effect of DM-SRF expression was
already apparent 10 h after CH11 treatment (not shown). From
these results, we infer that SRF cleavage by caspases is an
important early step in Fas-mediated apoptosis of BJAB cells.
DISCUSSION
In this paper, we have examined the cleavage of SRF, a
transcription factor involved in proliferative gene expression,
by caspases, the intracellular executioners of apoptosis. We
find that in BJAB cells, SRF is cleaved early after Fas-induced
apoptosis, at which point c-fos expression is down-regulated. In
vitro SRF is cleaved most efficiently by caspase 7 but also by
caspases 3 and 8, yielding two major cleavage fragments. SRF
cleavage fragments fail to support SRF-dependent reporter
expression, while expression of a cleavage-resistant form of
SRF suppresses apoptosis.
By a combination of deletion analysis and point mutagenesis,
caspase cleavage sites in SRF were mapped to two closely
spaced aspartates in the middle of the molecule. Cleavage
therefore occurs just carboxyl-terminal to the DNA-binding
core of SRF. Intriguingly, half of the aspartate residues in SRF
(6 of 12) are clustered in this region of the protein. Apart from
the core domain of SRF, which has been examined in some
detail (6), little is known about either the structure or function
of other SRF domains. Within the amino-terminal domain, the
only feature to have been studied is a cluster of phosphoryla-
tion sites that seems to influence the rate of formation and
stability of DNA complexes (11–14). Phosphorylation of one of
these residues (Ser103) was shown to correlate with transcrip-
FIG. 6. DM-SRF resists cleavage in BJAB cells. Cells were trans-
fected with expression vectors for SRF (lanes 1 and 2), EATA-SRF
(lanes 3 and 4), SASA-SRF (lanes 5 and 6), or DM-SRF (lanes 7 and 8).
After 24-h culture in low serum, cells were treated with CH11 () or left
untreated (), and after a further 6 h lysates were prepared and
assayed by immunoblotting (IB) with an amino-terminal anti-SRF an-
tibody. WT, wild type.
FIG. 7. DM-SRF expression suppresses apoptosis in BJAB
cells. a, cells transfected with pUC8 or the expression vectors pCMV-
wtSRF or pCMV-DM-SRF were untreated (hatched bars) or incubated
with CH11 for 20 h (solid bars). Fixed cells were stained with DAPI and
scored for apoptosis under a fluorescence microscope. Data are from two
individual experiments, whereby each experiment was scored (n  200)
twice independently. b and c, representative images of CH11-treated
cells transfected with pCMV-wtSRF and pCMV-DM-SRF, respectively.
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tional activation of c-fos, but its mutation had no detectable
effect on expression levels (15). A region toward the carboxyl
terminus of SRF has been shown to possess transactivation
potential, and this correlates with an ability to interact with
the larger subunit of TFIIF, the mammalian homologue of
yeast RAP74 (17, 18). Thus, caspase cleavage severs the trans-
activation domain of SRF from its DNA-binding domain.
We found that whereas full-length SRF enhanced SRE-de-
pendent transcription, SRF fragments corresponding to those
generated by caspase cleavage were transcriptionally inactive
or slightly inhibitory to reporter expression. To rule out any
influence of endogenous full-length SRF, these experiments
were performed with a reporter system consisting of a modified
SRF with altered DNA binding specificity and a corresponding
reporter. This system has been used extensively to unravel
SRE-mediated transcription responses to intracellular signal-
ing events (38, 43). Two different mechanisms can be envisaged
to account for these observations. On the one hand, the amino-
terminal cleavage fragment of SRF (NMS4) is able to dimerize
and bind DNA as well as full-length SRF (see e.g. Fig. 2c), but
since it lacks the carboxyl-terminal transactivation domain it is
unlikely to recruit a functional transcription complex. A trun-
cated form of SRF lacking part of the transactivation domain,
which is generated by alternate splicing at exon 5, has also
been shown to lack transactivation potential and act as a
trans-dominant inhibitor of SRF function (44). On the other
hand, the carboxyl-terminal cleavage fragment of SRF (SRFC),
which cannot be recruited to the promoter, may inhibit tran-
scription by squelching basal factors, for example TFIIF (18).
The two sites in SRF recognized and cleaved by caspases
conform to a weak consensus by which the P4 position preced-
ing the conserved P1 aspartate is a small polar or negatively
charged residue (45). Although these sites conform structurally
to those for caspase 3 (24), it was not possible to predict un-
equivocally which caspase(s) would be responsible for cleavage.
A comparison of active, recombinant caspases revealed that
caspase 7 cleaves SRF most effectively, but cleavage at one or
the other of the sites by caspases 3, 8, and 9 was also observed.
In addition, a distinct, albeit weak, pattern of SRF fragments
was generated by caspases 4 and 1, suggesting that other
aspartate residues in SRF may serve as cleavage sites. Since
the relative activity of each recombinant caspase was similar,
these assays serve to predict with some accuracy the identity of
the caspases responsible for SRF cleavage in vivo.
Caspases are activated by proteolytic cleavage in a hierar-
chical fashion (24). Thus, caspases activated early during
apoptosis by scaffold-mediated proteolysis at death receptors or
in association with the Apaf-1-cytochrome c complex (46, 47)
activate, in turn, other caspases that cleave predominantly
cellular target proteins. Consequently, the activation of initia-
tor caspases (e.g. caspases 8 and 9) is thought to determine the
onset of the apoptosis program, while effector caspases, includ-
ing caspases 3 and 7, serve as executioners in what has become
an irreversible process. However, this simple dichotomy may
not strictly apply. For example, several proteins are targets for
both initiator and effector caspases (24). Moreover, caspase 3
can activate procaspase 9 (48).
The presence of four SRF fragments (e.g. Fig. 3b) suggests
that once SRF is cleaved by caspase 7 or caspase 3 at one site,
its susceptibility to cleavage at the adjacent site is markedly
reduced. In contrast, weak caspase 3 cleavage of DM-SRF in
vitro at a suboptimal site suggests that this region in full-
length SRF is acutely sensitive to cleavage. Notably, both
cleavage sites are evolutionarily conserved from zebrafish to
humans, although the zebrafish homologue of SRF is truncated
at the carboxyl terminus and lacks residues beyond amino acid
244. In Drosophila SRF (blistered), mutations are present at
each site, but three additional aspartate residues are available
in this region of the protein.
Our results suggest that SRF cleavage may be a determining
step in the apoptosis of BJAB cells. First, fragments of SRF are
detectable just 2 h after CH11 treatment of BJAB cells, a time
point at which morphological changes are absent. Second, the
overexpression of SRF lacking caspase cleavage sites caused a
40% reduction in the induction of apoptotic cells 20 h after Fas
cross-linking. The interpretation of this result is complicated
by two factors. First, whereas 95% of untransfected cells are
clearly apoptotic 10 h after CH11 treatment (Fig. 2a), only 60%
of cells that survive electroporation undergo apoptosis in re-
sponse to CH11. The reason for this is currently obscure. Sec-
ond, only 50% of the cells take up and express the transfected
DNA, which implies that the effect of DM-SRF expression on
apoptosis is an underestimate. To circumvent these problems,
we attempted to generate stable BJAB cell lines overexpressing
wtSRF and DM-SRF. While the former was straightforward
(Fig. 2d), we were unable to generate a cell line expressing
DM-SRF, despite three attempts with two expression/selection
systems. Nonetheless, our results show that interference with
the cleavage of a single caspase target protein, in this case SRF,
appears to derail the apoptosis machinery. These observations
are also consistent with a previous finding that treatment of
Jurkat cells with phorbol ester, a potent inducer of IE genes,
prevents SRF cleavage and protects the cells against Fas-in-
duced apoptosis (49).
Caspases promote cell death in several ways. For example,
the proapoptotic proteins Bid and Bax are activated by caspase
cleavage (50, 51). Several protein kinases capable of activating
the stress-activated protein kinase/Jun N-terminal kinase
pathway are also cleaved by caspases to produce constitutively
active, proapoptotic kinases (52–54). Caspases also disrupt cell
survival by inactivating survival factors, such as Bcl-2 and
Bcl-XL (55, 56), but also by targeting components of survival
pathways (57–59). Survival pathways up-regulate several nu-
clear events, including IE gene expression, in which SRF is
involved. In this context, SRF has recently been linked to
expression of the Bcl-2-related survival factor MCL1 (60). Par-
adoxically, stress signals have also been shown to stimulate
expression of c-fos, a paradigm for SRF-regulated IE genes
(61–64). Thus, caspase cleavage of SRF may ensure the extinc-
tion of a subset of survival genes whose expression would
otherwise be maintained by cell stress signals.
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